Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy

This study has been completed.

Sponsor:

Collaborators:

other sponsors:Japanese MOPH

Labor and Welfare

Thai MOPH

Thai GPO

other collaborators: Bamrasnaradura Infectious Diseases Institute

Chiang Rai Hospital

King Chulalongkorn Memorial Hospital

Central General Chest Institute

The Research Institute of Tuberculosis (Japan)

Information provided by:

The HIV Netherlands Australia Thailand Research Collaboration

ClinicalTrials.gov Identifier:

NCT00476853

First received: May 20, 2007

Last updated: June 4, 2010

Last verified: June 2010

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	December 2009
Primary Completion Date:	September 2008 (Final data collection date for primary outcome measure)

No publications provided by The HIV Netherlands Australia Thailand Research Collaboration

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Sakornjun W, Gorowara M, Yamada N, Yanai H, Mitarai S, Ishikawa N, Cooper DA, Phanuphak P, Burger D, Ruxrungtham K. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther. 2008;13(4):529-36.

To Top